Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Ocular Immunology and Inflammation|February 28, 2023
Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular ProfileRoselie Achten, Chantal van Luijk, Judith Thijs, et al.
The Journal of Dermatological Treatment|June 21, 2021
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registryJart A F Oosterhaven, Lotte S Spekhorst, Junfen Zhang, et al.
JAMA Dermatology|November 2, 2022
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Floris Loeff, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2024
Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitisJulia Clabbers, Celeste Boesjes, Lotte Spekhorst, et al.
Expert Opinion on Biological Therapy|December 1, 2025
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatmentCeleste M Boesjes, Lian F van der Gang, Roselie E Achten, et al.
Allergy|July 15, 2022
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitisLotte S Spekhorst, Daphne Bakker, Julia Drylewicz, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|December 24, 2022
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registryEsmé Kamphuis, Celeste M Boesjes, Laura Loman, et al.
Acta Dermato-Venereologica|February 7, 2024
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay RegistryEsmé Kamphuis, Celeste M Boesjes, Laura Loman, et al.
The Journal of Dermatological Treatment|July 31, 2025
Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registryFlorence Vroman, Lisa P van der Rijst, Octavian I Bacoş-Cosma, et al.
Acta Dermato-Venereologica|January 31, 2022
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic DermatitisRoselie E Achten, Chantal Van Luijk, Lisa Van der Rijst, et al.
Pageof 6